



Contents lists available at ScienceDirect

Clinical Microbiology and Infection

journal homepage: www.clinicalmicrobiologyandinfection.org

Corrigendum to "Candidate anti-tuberculosis medicines and regimens under clinical evaluation" [Clin Microbiol Infect 30(9) (2024) 1131–1138]

Michael Hoelscher^{1, 2, 3, 4, *}, David Barros-Aguirre⁵, Masoud Dara⁶,
Norbert Heinrich^{1, 2, 3}, Eugene Sun⁷, Christoph Lange^{8, 9, 10, 11}, Simon Tiberi^{12, 13},
Charles Wells¹⁴

¹ Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany

² German Centre for Infection Research, Partner Site Munich, Munich, Germany

³ Fraunhofer Institute ITMP, Immunology, Infection and Pandemic Research, Munich, Germany

⁴ Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany

⁵ GSK, Tres Cantos, Spain

⁶ Otsuka Novel Products GmbH, Munich, Germany

⁷ TB Alliance, New York, NY, United States

⁸ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany

⁹ German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany

¹⁰ Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany

¹¹ Baylor College of Medicine and Texas Children Hospital, Global TB Program, Houston, TX, United States

¹² GSK, Brentford, United Kingdom

¹³ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

¹⁴ Bill & Melinda Gates Medical Research Institute, Cambridge, MA, United States

The authors regret that the following text on funding of this work was not included:

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.cmi.2024.06.016>.

* Corresponding author. Michael Hoelscher, Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, Leopoldstr 5, 80802 Munich, Germany.
E-mail address: hoelscher@lrz.uni-muenchen.de (M. Hoelscher).

<https://doi.org/10.1016/j.cmi.2025.10.001>

1198-743X/© 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: Hoelscher M et al., Corrigendum to "Candidate anti-tuberculosis medicines and regimens under clinical evaluation" [Clin Microbiol Infect 30(9) (2024) 1131–1138], Clinical Microbiology and Infection, <https://doi.org/10.1016/j.cmi.2025.10.001>